MyDx, Inc. announced a definitive agreement and statement of work with a contract research organization to commence clinical trials in Israel on its proprietary pain management formula that was derived from 50,000+ pre-clinical, crowd-sourced physiological data-points tracked by MyDx's Handheld Cannabis Tester and associated mobile app. Israel was chosen for its ability to fast track studies through the FDA as well as its expertise in the cannabis field. The study will be conducted in one of the leading hospitals in Israel, and will be overseen by the Israeli Ministry of Health. MyDx initially intends to find a pain management solution for people suffering from chronic pain, since pain is the number one ailment its consumers are seeking to alleviate with cannabis. When clinical trials are near complete, MyDx expects to conduct additional trials for its MyDx360 customers on various other areas of interest as well as the next most prioritized ailments in the company database as indicated by MyDx users. Clinical Trials for its pain management solution will begin on or around March of 2018, and should be completed by third quarter of 2018, with periodic updates on the status of results leading up to the completion of trials. The primary objective is to compare the efficacy, as measured by the assessment of the level of back pain, of MyDx formulated products patients with chronic neuropathic back pain. The secondary objective is to compare additional evidence of efficacy in the patients quality of life as it relates to sleep, anxiety and depression. The third objective is to validate MyDx EcoSmart Dosing Pen, Handheld Tester and resulting data, vthe efficacy of MyDx360 Delivery Mechanisms such as the Thin Film Strips used in the study and characterize safety profile of 'company' products.